Isavuconazole, a novel antifungal azole that displays excellent activity against yeasts and molds, may be an appealing candidate for antimold prophylaxis in ALL patients since it appears to have fewer serious adverse events and is a moderate CYP3A inhibitor with less DDIs in comparison with other azoles [68]. The gene discussed is CYP3A4; the disease is acute lymphoblastic leukemia.